SUN-VIIA, also known as Fexo-Base, is an advanced pharmaceutical intermediate with the CAS number 83799-24-0. It is the key intermediate in the synthesis of Fexofenadine Hydrochloride, a widely used second-generation antihistamine known for its non-sedative properties. SUN-VIIA plays a critical role in ensuring the efficacy and purity of the final active pharmaceutical ingredient (API), particularly in antihistamine formulations. Its high chemical stability and compliance with GMP manufacturing standards make it an essential component for leading pharmaceutical companies involved in allergy treatment formulations.
SUN-VIIA, also known as Fexo-Base, is an advanced pharmaceutical intermediate with the CAS number 83799-24-0. It is the key intermediate in the synthesis of Fexofenadine Hydrochloride, a widely used second-generation antihistamine known for its non-sedative properties. SUN-VIIA plays a critical role in ensuring the efficacy and purity of the final active pharmaceutical ingredient (API), particularly in antihistamine formulations. Its high chemical stability and compliance with GMP manufacturing standards make it an essential component for leading pharmaceutical companies involved in allergy treatment formulations.
.3d8f8f41.svg)
Pharmaceutical
.3556d45a.svg)
Pharmaceutical Actives & Precursors
Antihistamines
Included in Quote
Included in Quote
Included in Quote
Included in Quote
.7767eb0f.png)
Chemical Properties & Specifications
Primary active pharmaceutical ingredient (API) in antihistamine formulations.
Used in the manufacture of non-sedating antihistamines, effective for treating seasonal allergic rhinitis, chronic urticaria, and other allergic reactions.
Key API in the production of generic versions of antihistamines in oral solid dosage forms like tablets and capsules.
Sometimes formulated with other decongestants or anti-allergic agents to enhance therapeutic efficacy.
SUN-VIIA (Fexo-Base) is a pharmaceutical intermediate used in the synthesis of Fexofenadine, a widely used antihistamine for treating allergic reactions, rhinitis, and chronic urticaria.
Primarily used in the pharmaceutical industry as a key API intermediate for antihistamine drug manufacturing.
Yes, it is subject to pharmaceutical regulatory compliance in different regions depending on its end use in API production.
SUN-VIIA is a critical API intermediate in the production of Fexofenadine HCl, ensuring consistent therapeutic efficacy and regulatory compliance in antihistamine drug manufacturing. It provides high yield and chemical purity, crucial for synthesis optimization in pharmaceutical R&D labs. This intermediate plays a key role in producing Fexofenadine-based allergy medications, known for their non-drowsy relief from allergies.
The high purity standards of SUN-VIIA minimize impurities in the final API, leading to enhanced product safety and reduced batch rejections. It ensures controlled reactivity and stereoselectivity, resulting in a highly pure and bioavailable antihistamine API. It enables safer and more effective allergy relief, providing fast-acting, non-sedative treatment.
Requires GMP manufacturing, COA (Certificate of Analysis), and compliance with ICH-Q7 and US FDA guidelines for pharmaceutical intermediates. Supports documentation for regulatory submissions and validation batches in drug development pipelines. Ensures the allergy medicines they take are safe, high-quality, and regulatory compliant.
